Background: Increased circulating plasma urate concentration is associated with an increased risk of coronary heart disease, but the extent of any causative effect of urate on risk of coronary heart disease is still unclear. In this study, we aimed to clarify any causal role of urate on coronary heart disease risk using Mendelian randomisation analysis.
Methods: We first did a fixed-effects meta-analysis of the observational association of plasma urate and risk of coronary heart disease. We then used a conventional Mendelian randomisation approach to investigate the causal relevance using a genetic instrument based on 31 urate-associated single nucleotide polymorphisms (SNPs). To account for potential pleiotropic associations of certain SNPs with risk factors other than urate, we additionally did both a multivariable Mendelian randomisation analysis, in which the genetic associations of SNPs with systolic and diastolic blood pressure, HDL cholesterol, and triglycerides were included as covariates, and an Egger Mendelian randomisation (MR-Egger) analysis to estimate a causal effect accounting for unmeasured pleiotropy.
Findings: In the meta-analysis of 17 prospective observational studies (166 486 individuals; 9784 coronary heart disease events) a 1 SD higher urate concentration was associated with an odds ratio (OR) for coronary heart disease of 1·07 (95% CI 1·04-1·10). The corresponding OR estimates from the conventional, multivariable adjusted, and Egger Mendelian randomisation analysis (58 studies; 198 598 individuals; 65 877 events) were 1·18 (95% CI 1·08-1·29), 1·10 (1·00-1·22), and 1·05 (0·92-1·20), respectively, per 1 SD increment in plasma urate.
Interpretation: Conventional and multivariate Mendelian randomisation analysis implicates a causal role for urate in the development of coronary heart disease, but these estimates might be inflated by hidden pleiotropy. Egger Mendelian randomisation analysis, which accounts for pleiotropy but has less statistical power, suggests there might be no causal effect. These results might help investigators to determine the priority of trials of urate lowering for the prevention of coronary heart disease compared with other potential interventions.
Funding: UK National Institute for Health Research, British Heart Foundation, and UK Medical Research Council.
Copyright © 2016 White et al. Open Access article distributed under the terms of CC BY. Published by Elsevier Ltd.. All rights reserved.
Apolipoprotein(a) isoform size, lipoprotein(a) concentration, and coronary artery disease: a mendelian randomisation analysis.Lancet Diabetes Endocrinol. 2017 Jul;5(7):524-533. doi: 10.1016/S2213-8587(17)30088-8. Epub 2017 Apr 10. Lancet Diabetes Endocrinol. 2017. PMID: 28408323 Free PMC article.
Extending the MR-Egger method for multivariable Mendelian randomization to correct for both measured and unmeasured pleiotropy.Stat Med. 2017 Dec 20;36(29):4705-4718. doi: 10.1002/sim.7492. Epub 2017 Sep 27. Stat Med. 2017. PMID: 28960498 Free PMC article.
Causal Assessment of Serum Urate Levels in Cardiometabolic Diseases Through a Mendelian Randomization Study.J Am Coll Cardiol. 2016 Feb 2;67(4):407-416. doi: 10.1016/j.jacc.2015.10.086. J Am Coll Cardiol. 2016. PMID: 26821629 Free PMC article. Clinical Trial.
Serum uric acid levels and multiple health outcomes: umbrella review of evidence from observational studies, randomised controlled trials, and Mendelian randomisation studies.BMJ. 2017 Jun 7;357:j2376. doi: 10.1136/bmj.j2376. BMJ. 2017. PMID: 28592419 Free PMC article. Review.
Mendelian randomization to assess causal effects of blood lipids on coronary heart disease: lessons from the past and applications to the future.Curr Opin Endocrinol Diabetes Obes. 2016 Apr;23(2):124-30. doi: 10.1097/MED.0000000000000230. Curr Opin Endocrinol Diabetes Obes. 2016. PMID: 26910273 Free PMC article. Review.
Cited by 29 articles
Exploiting horizontal pleiotropy to search for causal pathways within a Mendelian randomization framework.Nat Commun. 2020 Feb 21;11(1):1010. doi: 10.1038/s41467-020-14452-4. Nat Commun. 2020. PMID: 32081875 Free PMC article.
Asymptomatic hyperuricaemia: a silent activator of the innate immune system.Nat Rev Rheumatol. 2020 Feb;16(2):75-86. doi: 10.1038/s41584-019-0334-3. Epub 2019 Dec 10. Nat Rev Rheumatol. 2020. PMID: 31822862 Review.
Genetically determined serum urate levels and cardiovascular and other diseases in UK Biobank cohort: A phenome-wide mendelian randomization study.PLoS Med. 2019 Oct 18;16(10):e1002937. doi: 10.1371/journal.pmed.1002937. eCollection 2019 Oct. PLoS Med. 2019. PMID: 31626644 Free PMC article.
Target genes, variants, tissues and transcriptional pathways influencing human serum urate levels.Nat Genet. 2019 Oct;51(10):1459-1474. doi: 10.1038/s41588-019-0504-x. Epub 2019 Oct 2. Nat Genet. 2019. PMID: 31578528 Free PMC article.
The association between hyperuricemia and coronary artery calcification development: A systematic review and meta-analysis.Clin Cardiol. 2019 Nov;42(11):1079-1086. doi: 10.1002/clc.23266. Epub 2019 Sep 30. Clin Cardiol. 2019. PMID: 31571239 Free PMC article.
- Terkeltaub RA. Update on gout: new therapeutic strategies and options. Nat Rev Rheumatol. 2010;6:30–38. - PubMed
- Davis N. The cardiovascular and renal relations and manifestations of gout. JAMA. 1897;29:261–262.
- Waring WS, McKnight JA, Webb DJ, Maxwell SRJ. Uric acid restores endothelial function in patients with type 1 diabetes and regular smokers. Diabetes. 2006;55:3127–3132. - PubMed
- G1001799/Medical Research Council/United Kingdom
- CZB/4/672/Chief Scientist Office/United Kingdom
- MR_UU_12013/5/Medical Research Council/United Kingdom
- RG/13/2/30098/British Heart Foundation/United Kingdom
- RG/08/008/25291/British Heart Foundation/United Kingdom
- PG/13/66/30442/British Heart Foundation/United Kingdom
- G0802432/Medical Research Council/United Kingdom
- R01 HL036310/HL/NHLBI NIH HHS/United States
- MR/K006215/1/Medical Research Council/United Kingdom
- 5R01AG13196/AG/NIA NIH HHS/United States
- MC_UU_12019/1/Medical Research Council/United Kingdom
- MR_UU_12013/8/Medical Research Council/United Kingdom
- RG/08/013/25942/British Heart Foundation/United Kingdom
- MC_UU_12015/1/Medical Research Council/United Kingdom
- MC_U106179471/Medical Research Council/United Kingdom
- G0500877/Medical Research Council/United Kingdom
- MC_UU_12015/2/Medical Research Council/United Kingdom
- MC_U106179472/Medical Research Council/United Kingdom
- RG/07/008/23674/British Heart Foundation/United Kingdom
- 5R01 HL036310/HL/NHLBI NIH HHS/United States
- MC_UU_12013/1/Medical Research Council/United Kingdom
- 057762/Wellcome Trust/United Kingdom
- RG/13/5/30112/British Heart Foundation/United Kingdom
- RG/97006/British Heart Foundation/United Kingdom
- MR_UU_12013/1/Medical Research Council/United Kingdom
- G0902037/Medical Research Council/United Kingdom
- MR/K006584/1/Medical Research Council/United Kingdom
- MR/K013351/1/Medical Research Council/United Kingdom
- R01 AG013196/AG/NIA NIH HHS/United States
- PG/12/71/29684/British Heart Foundation/United Kingdom
- 068545/Z/02/Wellcome Trust/United Kingdom
- HS06516/HS/AHRQ HHS/United States
- RG/13/16/30528/British Heart Foundation/United Kingdom
- MC_UU_12013/5/Medical Research Council/United Kingdom
- MC_UU_12013/8/Medical Research Council/United Kingdom
- RG/10/12/28456/British Heart Foundation/United Kingdom